Anti High-Triglyceride Drug Boosts Acasti Pharma (ACST); Volatile Session for Biostar Pharma (BSPM)


Shares of Acasti Pharma Inc. (Nasdaq:ACST) climbed the touch the $3.09 mark ACST stock in intraday trading Wednesday after the company said that the results from a bioavailability study evaluating its high-triglyceride fighter CaPre (omega-3 phospholipid) in healthy volunteers showed similar safety profile to GlaxoSmithKline plc‘s (NYSE:GSK) FDA-approved hypertriglyceridemia drug LOVAZA

ACST stock closed at $2.81, up $1.56 (or +124.80%) and 5.32M of its shares changed hands during the day, representing a large increase in activity versus its average volume (3m) of 25,867

Acasti Pharma, which focuses on the research, development, and commercialization of therapies for the treatment of various cardiometabolic disorders, has 10.71M Shares Outstanding, Market Capitalization (intraday) of $30.09M and ACST stock 52-week range is between $1.20 and $3.66 per share



Biostar Pharmaceuticals Inc. (Nasdaq:BSPM) stock soared 65.37% (or +$1.34) to $3.39 with a total volume of 12.18M shares traded on Wednesday. There appears to be no relevant recent information from the PRC-based company that may explain the significant bullish activity in the stock

Biostar recently reported a net loss of ($6.9) million for the second quarter 2016 versus a net loss of ($0.5) million in the same period the prior year

Biostar Pharmaceuticals, which develops, manufactures, and markets pharmaceutical and health supplement products in China, has 2.21M Shares Outstanding, Market Capitalization (intraday) of $7.49M and BSPM stock one-year range is from $1.08 to $6.59 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at